Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene FGFR2
Variant N549K
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions FGFR2 N549K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549K confers a gain of function to the Fgfr2 protein resulting in a growth advantage relative to wild-type Fgfr2 in a competition assay, increased transformation activity in cultured cells (PMID: 34272467), oncogenic transformation in culture (PMID: 18552176, PMID: 17803937, PMID: 29533785) and increased MAPK pathway signaling in cultured cells (PMID: 19147536).
Associated Drug Resistance Y
Category Variants Paths

FGFR2 mutant FGFR2 act mut FGFR2 N549K

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000141.5
gDNA chr10:g.121498520A>C
cDNA c.1647T>G
Protein p.N549K
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_023029.2 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_000141.5 chr10:g.121498520A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_001144919 chr10:g.121488066G>C c.1647C>G p.N549K RefSeq GRCh38/hg38
NM_001144915.2 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_023029 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_000141.4 chr10:g.121498520A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_000141 chr10:g.121498520A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_001144915 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_001144919.1 chr10:g.121488066G>C c.1647C>G p.N549K RefSeq GRCh38/hg38
NM_001144915.1 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38
NM_001144919.2 chr10:g.121488066G>C c.1647C>G p.N549K RefSeq GRCh38/hg38
NM_023029.2 chr10:g.121488063A>C c.1647T>G p.N549K RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 K310R FGFR2 N549K endometrial carcinoma sensitive FIIN-1 Preclinical Actionable In a preclinical study, FIIN-1 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520). 20338520
FGFR2 K310R FGFR2 N549K endometrial cancer sensitive Debio 1347 Preclinical Actionable In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980). 25169980
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO4987655 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit RO5126766 Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial carcinoma no benefit Selumetinib Preclinical - Cell culture Actionable In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159). 26438159
FGFR2 K310R FGFR2 N549K endometrial cancer predicted - sensitive Futibatinib Preclinical - Cell culture Actionable In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in an endometrial cancer cell line harboring FGFR2 K310R and FGFR2 N549K in culture (PMID: 32973082). 32973082
FGFR2 K310R FGFR2 N549K endometrial adenocarcinoma sensitive RLY-4008 Preclinical - Cell line xenograft Actionable In a preclinical study, RLY-4008 inhibited proliferation of an endometrial adenocarcinoma cell line harboring FGFR2 N549K and FGFR K310R in culture, and led to tumor regression in a cell line xenograft model (PMID: 37270847). 37270847
FGFR2 K310R FGFR2 N549K endometrial adenocarcinoma sensitive Futibatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Lytgobi (futibatinib) treatment led to tumor regression in a cell line xenograft model of endometrial adenocarcinoma harboring FGFR2 N549K and FGFR2 K310R (PMID: 37270847). 37270847